Free Trial

Little House Capital LLC Has $402,000 Holdings in Danaher Corporation (NYSE:DHR)

Danaher logo with Medical background

Little House Capital LLC reduced its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 81.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,963 shares of the conglomerate's stock after selling 8,657 shares during the quarter. Little House Capital LLC's holdings in Danaher were worth $402,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of DHR. Vanguard Group Inc. raised its position in Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock worth $13,715,641,000 after purchasing an additional 315,912 shares during the last quarter. Geode Capital Management LLC raised its position in Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after purchasing an additional 315,446 shares during the last quarter. Norges Bank bought a new position in Danaher in the 4th quarter worth approximately $2,130,740,000. Northern Trust Corp raised its position in Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after purchasing an additional 992,594 shares during the last quarter. Finally, Capital World Investors raised its position in Danaher by 32.7% in the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE DHR opened at $198.20 on Friday. The firm has a market cap of $141.84 billion, a PE ratio of 38.48, a PEG ratio of 2.83 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a fifty day moving average price of $194.84 and a 200 day moving average price of $208.52.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. Research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher's payout ratio is 24.85%.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Barclays restated an "overweight" rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research report on Tuesday. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Robert W. Baird dropped their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Guggenheim reiterated a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $248.61.

Check Out Our Latest Report on Danaher

Insider Activity

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA: Another 200% Growth Ahead? (PLUS 2 Companies Riding Along)
3 Rising Stocks You’ll Want on Your Watchlist
Trillions in Defense Spending—3 Disruptive Stocks Set to Double

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines